Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

About Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:REGN
  • CUSIP: 75886F10
  • Web:
  • Market Cap: $48.05 billion
  • Outstanding Shares: 105,571,000
Average Prices:
  • 50 Day Moving Avg: $409.68
  • 200 Day Moving Avg: $385.55
  • 52 Week Range: $325.35 - $464.40
  • Trailing P/E Ratio: 55.10
  • Foreward P/E Ratio: 29.71
  • P/E Growth: 1.88
Sales & Book Value:
  • Annual Revenue: $4.98 billion
  • Price / Sales: 9.65
  • Book Value: $46.09 per share
  • Price / Book: 9.88
  • EBIDTA: $1.55 billion
  • Net Margins: 18.10%
  • Return on Equity: 22.51%
  • Return on Assets: 14.58%
  • Debt-to-Equity Ratio: 0.08%
  • Current Ratio: 2.56%
  • Quick Ratio: 2.24%
  • Average Volume: 916,644 shs.
  • Beta: 1.44
  • Short Ratio: 2.82

Frequently Asked Questions for Regeneron Pharmaceuticals (NASDAQ:REGN)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its quarterly earnings data on Thursday, May, 4th. The company reported $2.92 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion for the quarter, compared to analysts' expectations of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The business's revenue was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.57 EPS. View Regeneron Pharmaceuticals' Earnings History.

When will Regeneron Pharmaceuticals make its next earnings announcement?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Regeneron Pharmaceuticals.

Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2017?

24 brokerages have issued 12 month price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $345.00 to $598.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $436.00 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals.

What are analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

  • 1. Cowen and Company analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)
  • 2. According to Zacks Investment Research, "Regeneron’s key growth driver, Eylea, continues to drive revenues at the company and the company is expanding the drug's label for additional indications. Regeneron received a major boost when Praluent became the first PCSK9 inhibitor to be approved (Jul 2015) in the U.S and the EU (Sep 2015). Although sales of Praluent have failed to impress due to the present payer utilization management restrictions in the U.S. and limited market access in Europe, the drug is still expected to have blockbuster potential. The FDA recently approved the companies' new supplemental Biologics License Application (sBLA) for a once-monthly, 300 mg dose of Praluent(alirocumab) Injection for the treatment of adults with high low-density. Investors should focus on pipeline catalysts - dupilumab and sarilumab. Shares of the company have also outperformed the industry in the last three months. Estimates have been stable in the last thirty days." (4/27/2017)
  • 3. BMO Capital Markets analysts commented, "We raise our price target to $412 but maintain our Market Perform rating on REGN following Dupixent approval in adult atopic dermatitis. While the approval was widely expected and reflects the strength of Dupixent's clinical profile, we believe the $37k gross price (~$30k net) is higher than expected (BMO: ~$25k prior) and could lead to even more aggressive management by payors. Thus, while we have updated our model to reflect Dupixent's actual price, we have slowed our ramp on our expectation for increased access restrictions given the therapy's high price." (3/28/2017)
  • 4. Robert W. Baird analysts commented, "We surveyed 30 dermatologists treating ~134 moderate-to-severe AD patients each on their expectations around the launches for Pfizer's Eucrisa and Regeneron/Sanofi's Dupixent, set for approval tomorrow. Docs highlighted the significant need for new mechanisms and therapeutic alternatives. Importantly, physician sentiment points to a market for Dupixent of about 300,000-350,000 patients, in line with management's expectations. We wouldn't be surprised to see an exceptionally strong launch here, but we continue to point out that consensus expectations are already building that in." (3/28/2017)

Who are some of Regeneron Pharmaceuticals' key competitors?

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:

  • P. Roy Vagelos M.D., Chairman of the Board
  • Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director
  • Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance
  • Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply
  • Neil Stahl Ph.D., Executive Vice President - Research and Development
  • Robert J. Terifay, Executive Vice President - Commercial
  • Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary
  • Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation
  • Peter Powchik M.D., Senior Vice President - Clinical Development
  • George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director

Who owns Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (6.28%), BlackRock Inc. (5.83%), Wellington Management Group LLP (5.82%), Vanguard Group Inc. (4.86%), State Street Corp (3.20%) and Artisan Partners Limited Partnership (1.83%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos, Peter Powchik, Plew Daniel P Van and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, Winslow Capital Management LLC, Ameriprise Financial Inc., Manning & Napier Advisors LLC, Morgan Stanley, UBS Asset Management Americas Inc. and APG Asset Management N.V.. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Brown and P Roy Vagelos. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Capital Management LLC, Wellington Management Group LLP, Harding Loevner LP, Bank of New York Mellon Corp, Vanguard Group Inc., American Century Companies Inc. and State Street Corp. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy Regeneron Pharmaceuticals stock?

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $455.17.

MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  882 (Vote Outperform)
Underperform Votes:  654 (Vote Underperform)
Total Votes:  1,536
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) (?)
Ratings Breakdown: 13 Hold Ratings, 11 Buy Ratings
Consensus Rating:Hold (Score: 2.46)
Consensus Price Target: $436.00 (4.21% downside)

Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Sanford C. BernsteinReiterated RatingOutperformHighView Rating Details
5/15/2017Credit Suisse Group AGReiterated RatingBuy$485.00LowView Rating Details
5/15/2017Cowen and CompanyReiterated RatingHold$380.00LowView Rating Details
5/15/2017BMO Capital MarketsBoost Price TargetHold$412.00 -> $421.00LowView Rating Details
5/8/2017Barclays PLCBoost Price TargetEqual Weight$375.00 -> $400.00LowView Rating Details
5/5/2017Canaccord GenuityUpgradeHold -> Buy$375.00 -> $484.00LowView Rating Details
5/4/2017Oppenheimer Holdings Inc.Reiterated RatingHoldLowView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingHold$357.00LowView Rating Details
3/29/2017BTIG ResearchReiterated RatingBuy$460.00MediumView Rating Details
3/28/2017Leerink SwannSet Price TargetBuy$448.00LowView Rating Details
3/28/2017Robert W. BairdReiterated RatingNeutral$369.00LowView Rating Details
3/17/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
3/8/2017Piper Jaffray CompaniesSet Price TargetBuy$446.00LowView Rating Details
2/16/2017Goldman Sachs Group IncDowngradeBuy -> NeutralN/AView Rating Details
2/10/2017Morgan StanleyLower Price TargetEqual Weight$370.00 -> $367.00N/AView Rating Details
2/10/2017Citigroup IncReiterated RatingBuy$420.00N/AView Rating Details
1/22/2017JPMorgan Chase & Co.Set Price TargetHold$440.00N/AView Rating Details
1/10/2017Wells Fargo & CoReiterated RatingMarket PerformN/AView Rating Details
1/8/2017Evercore ISISet Price TargetHold$421.00N/AView Rating Details
1/6/2017Royal Bank of CanadaReiterated RatingOutperform$626.00 -> $598.00N/AView Rating Details
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 -> $345.00N/AView Rating Details
12/28/2016ArgusReiterated RatingBuy$450.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/AView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/AView Rating Details
3/17/2016SunTrust Banks, Inc.Lower Price TargetNeutral$450.00 -> $410.00N/AView Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00N/AView Rating Details
2/11/2016Bank of America CorpReiterated RatingBuy$649.00 -> $525.00N/AView Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageOutperform$615.00N/AView Rating Details
8/4/2015Deutsche Bank AGReiterated RatingBuy$650.00 -> $720.00N/AView Rating Details
7/22/2015Northland SecuritiesInitiated CoverageMarket Perform$560.00N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Earnings by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Earnings History by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017$2.50$2.92$1.30 billion$1.32 billionViewListenView Earnings Details
2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListenView Earnings Details
11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/AView Earnings Details
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)
Current Year EPS Consensus Estimate: $12.68 EPS
Next Year EPS Consensus Estimate: $15.32 EPS


Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 68.83%
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017P Roy VagelosChairmanSell9,295$458.14$4,258,411.30View SEC Filing  
5/12/2017Michael S BrownDirectorSell3,000$450.00$1,350,000.00View SEC Filing  
3/29/2017Michael S BrownDirectorSell1,000$400.00$400,000.00View SEC Filing  
1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58View SEC Filing  
12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.00View SEC Filing  
11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.00View SEC Filing  
11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.00View SEC Filing  
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.00View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.00View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.01View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.00View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.00View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.32View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.45View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.00View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.17View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.00View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.00View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.00View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.05View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.58View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.00View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.16View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.20View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.84View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.71View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.00View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.50View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.36View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.93View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.00View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.83View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.16View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.09View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.00View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.00View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Regeneron Pharmaceuticals (NASDAQ:REGN)
Latest Headlines for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateHeadline logoCowen and Company Reaffirms "Hold" Rating for Regeneron Pharmaceuticals Inc (REGN) - May 29 at 12:38 AM logoRegeneron Pharmaceuticals Inc (REGN) PT Raised to $421.00 - May 29 at 12:38 AM logoRegeneron Pharmaceuticals Inc (REGN) Stock Rating Reaffirmed by Credit Suisse Group AG - May 29 at 12:38 AM logoRegeneron Pharmaceuticals Inc (REGN) Earns "Outperform" Rating from Sanford C. Bernstein - May 27 at 1:24 PM logoRegeneron Pharmaceuticals Inc (REGN) Chairman Sells $4,258,411.30 in Stock - May 26 at 7:20 PM logoRegeneron (REGN) Says Data on ANGPTL3/Evinacumab Published in NEJM - - May 24 at 7:54 PM logoRegeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH - May 24 at 7:54 PM logoBlog Coverage: Celgene Reported Positive Late Stage Results from Trial of Ozanimod in Patients with Relapsing Multiple Sclerosis - May 24 at 9:48 AM logoBiotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data - May 24 at 9:48 AM logoSanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis - May 23 at 6:55 PM logoStock Traders Purchase High Volume of Put Options on Regeneron Pharmaceuticals (REGN) - May 23 at 1:22 PM logoRegeneron (REGN), Sanofi (SNY) Announce FDA Approval of Kevzara for RA - May 23 at 9:39 AM logoSanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the ... - May 23 at 9:39 AM logoSanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately - May 22 at 6:37 PM logoBRIEF-Regeneron, Sanofi RA drug wins FDA nod; co's price it at $39,000/patient/yr - May 22 at 6:37 PM logoETFs with exposure to Regeneron Pharmaceuticals, Inc. : May 22, 2017 - May 22 at 6:37 PM logoRegeneron And Sanofi Have A Near-Term FDA Catalyst - May 22 at 6:37 PM logoRegeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients - May 22 at 6:37 PM logoSanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients - May 22 at 6:37 PM logoThese 3 Biotech Stocks Have Ballooned in 2017, but Will They Pop? - May 22 at 9:23 AM logoCompugen (CGEN) Worth a Look: Stock Adds 10.4% in Session - May 22 at 9:23 AM logoXBI, VRTX, REGN, EXAS: Large Inflows Detected at ETF - May 19 at 12:22 PM logoRegeneron Pharmaceuticals: Post-Earnings Analysis - May 19 at 12:21 PM logoRecovering Biotech Stock Enters Buy Zone; Earns Rating Upgrade - May 19 at 12:21 PM logoRegeneron CEO in Boston: drug pricing could be 'the undoing of our industry' - May 19 at 12:21 PM logoVetr Upgrade's REGN's On Price Growth Following Positive Guidance - May 19 at 12:21 PM logoRegeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 - May 19 at 12:21 PM logoVetr Inc. Lowers Regeneron Pharmaceuticals Inc (REGN) to Strong Sell - May 16 at 12:34 AM logoMichael S. Brown Sells 3,000 Shares of Regeneron Pharmaceuticals Inc (REGN) Stock - May 15 at 7:11 PM logoWsfs Capital Management, Llc Buys Regeneron Pharmaceuticals Inc, Williams Inc, BB&T Corp, ... - Nasdaq - May 14 at 11:06 AM logoRegeneron Pharmaceuticals Inc (REGN) Receives Average Rating of "Hold" from Brokerages - May 12 at 8:50 PM logoIs Regeneron Pharmaceuticals Stock Still a Buy After Its Big Bounce? - May 12 at 12:37 PM logoBiotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death - May 10 at 11:18 AM logoRegeneron Pharmaceuticals (REGN) Shares March Higher, Can It Continue? - May 9 at 10:51 AM logoRegeneron Pharmaceuticals Inc (REGN) Announces Quarterly Earnings Results - May 8 at 5:28 PM logoBRIEF-Regeneron and Inovio enter immuno-oncology clinical study agreement - May 8 at 11:47 AM logoRegeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy - May 8 at 11:47 AM logoInovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy - May 8 at 11:47 AM logoRegeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer - May 8 at 11:47 AM logoEdited Transcript of REGN earnings conference call or presentation 4-May-17 12:30pm GMT - May 8 at 11:47 AM logoRegeneron Pharmaceuticals Inc (REGN) Rating Reiterated by Barclays PLC - May 8 at 11:43 AM logoRegeneron shares poised for rebound: Barron's - May 7 at 8:01 PM logoRegeneron Pharmaceuticals Inc (REGN) Given a $421.00 Price Target by BMO Capital Markets Analysts - May 7 at 11:46 AM logoCowen and Company Reaffirms Hold Rating for Regeneron Pharmaceuticals Inc (REGN) - May 7 at 10:02 AM logoRegeneron Pharmaceuticals' (REGN) "Hold" Rating Reaffirmed at Oppenheimer Holdings Inc. - May 7 at 8:14 AM logoRegeneron Pharmaceuticals Sees Unusually High Options Volume (REGN) - May 7 at 7:28 AM logoRegeneron Pharmaceuticals Inc (REGN) Lifted to "Buy" at Canaccord Genuity - May 6 at 3:22 PM logoRegeneron Pharmaceuticals Inc (REGN) Earns "Buy" Rating from Credit Suisse Group AG - May 6 at 1:32 PM logoRegeneron Pharmaceuticals Reaches Analyst Target Price - May 6 at 8:12 AM logoRegeneron Announces Upcoming Investor Conference Presentations - May 6 at 8:12 AM



Regeneron Pharmaceuticals (REGN) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff